← boardnext 2027-02next 2027-06
CRVS
Rivus Pharmaceuticals, Inc.distress 4/10 · elevated risk$13.54-3%today-47% from 52w high
Immunology / Inflammation 1Oncology 1
Lead: Lymphoma · target ITK · est. market ~$18B (approx, global)
Revenue
pre-revenue
Liquidity
$40M
Runway
1.1 yrs
Shares 1y
+13%
Price & events
-46.9% over 6M
CatalystRating changeDilutionFinancingdashed = today
-3.2%
1D
-5.1%
1W
+7.2%
1M
-15.5%
3M
-46.1%
6M
+189.9%
1Y
+507.2%
2Y
+501.8%
5Y
+258.2%
All
Overview
- Market Cap
- $1.14B
- Volume
- 71.38K
- 52 Week Range
- $4.10 – $25.52
- Total Shares
- 84.09M
- Float Shares
- 72.76M
- Short %
- 25.44%
- % Held by Insiders
- 3.51%
- % Held by Institutions
- 85.57%
- RVOL
- 0.06x
- Beta
- 0.82
Pipeline stages · 3 programs
HU6
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Soquelitinib, Belinostat, Pralatrexate
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
CPI-818
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 5 trials · 3 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-02 Estimated 50% readout ~2027-03-18 | Phase 2 | HU6 | MASH - Metabolic Dysfunction-Associated Steatohepatitis | — | recruiting |
| 2027-06 Estimated 50% readout ~2027-07-16 | Phase 2 | Soquelitinib | Atopic Dermatitis, Atopic Dermatitis Eczema, Eczema, Eczema, Atopic | — | recruiting |
| 2027-11 Estimated 50% readout ~2028-01-15 | Phase 3 | Soquelitinib, Belinostat, Pralatrexate | Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T-cell Lymphoma, Follicular T-Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype, Systemic Anaplastic Large Cell Lymphoma, Lymphoma, T-Cell, Peripheral, Lymphoma, T-Cell | — | recruiting |
| 2026-04-30 | Phase 1 | CPI-818 | T-cell Lymphoma | 151 | active not recruiting |
| 2026-01-28 | Phase 1 | Soquelitinib | Atopic Dermatitis | 82 | completed |
Catalyst news & presentations · 3
- 2026-08-06Estimated 45%earningsEarningsEarnings releaseyahoo
- first quarter of 2026trial initiationsecondaryPhase 2soquelitinib · Initiate Phase 2 trial in patients who failed prior topical or systemic therapySEC 8-K
- second quarter 2025conferencedata presentationsecondaryPhase 1soquelitinib · Full results from all four study cohortsSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $33 (+146% upside) · 6 analysts
- 2026-04-17Goldman SachsBuy
- 2026-03-13OppenheimerOutperform
- 2026-01-22JefferiesBuy
- 2026-01-21OppenheimerOutperform
- 2026-01-21BarclaysOverweight
- 2026-01-20HC Wainwright & Co.Buy
Competitors — ITK
- none identified
Recent news
- 2026-07-22Corvus Pharmaceuticals Announces Board Leadership Transition - TipRanks
- 2026-07-21Corvus Pharmaceuticals (CRVS) Q1 2026 earnings summary - Quartr
- 2026-07-11Corvus Pharmaceuticals (CRVS) Proxy filing Summary - Quartr
- 2026-07-10CRVS News | CORVUS PHARMACEUTICALS INC (NASDAQ:CRVS) - ChartMill
- 2026-07-08Corvus Pharmaceuticals (CRVS) Q1 2025 earnings summary - Quartr
- 2026-07-08Corvus Pharmaceuticals (CRVS) Q4 2024 earnings summary - Quartr
- 2026-06-27Is Corvus Pharmaceuticals (CRVS) Still Undervalued After Its Share Price Jump? - Sahm
- 2026-06-27Corvus Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:CRVS) - TradingView
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.